Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cetrorelix (Cetrotide) vs Pegvisomant (Somavert)
An educational, source-based comparison of Cetrorelix (Cetrotide) and Pegvisomant (Somavert) — how each peptide works, what it's researched for, and what to know before going deeper.
GnRH antagonist used in IVF to prevent premature ovulation.
Synthetic decapeptide that competitively blocks pituitary GnRH receptors, preventing LH surge during controlled ovarian stimulation.
- IVF / controlled ovarian stimulation
- • FDA-approved.
- • Used under specialist supervision.
Pegylated GH receptor antagonist for acromegaly.
Genetically engineered analog of human GH with site-directed mutations blocking functional dimerization of the GH receptor; pegylation extends half-life. Lowers IGF-1 without lowering GH.
- Acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs
- • FDA-approved.
- • Monitor LFTs; tumor monitoring via MRI required.
- • Lipohypertrophy at injection sites.
Cetrorelix (Cetrotide) vs Pegvisomant (Somavert) — Key differences
- Class: Cetrorelix (Cetrotide) is classified as GnRH Antagonist · Reproductive, while Pegvisomant (Somavert) is GH Receptor Antagonist · Endocrine.
- Primary research focus: Cetrorelix (Cetrotide) — ivf / controlled ovarian stimulation; Pegvisomant (Somavert) — acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs.
- Tag: FDA-Approved · Fertility vs FDA-Approved · Endocrine.